Men with localized prostate cancer who received five sessions of focused radiation had cancer control similar to men who had their prostate removed, eight years after treatment, in a small British trial presented Sept. 28 at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
At eight years, 91% of men treated with stereotactic body radiotherapy (SBRT) were free of cancer recurrence, compared with 84% of men who had surgery. That gap was not statistically significant, so the trial cannot say one treatment controlled cancer better than the other.
